相关实验视频

Updated: Jul 13, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.3K

在NSCLC的临床背景下,IL-1β调节的前景充满希望

François Ghiringhelli1, Cédric Rébé1

  • 1Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, UMR INSERM 1231, TIRECs Team, Equipe Labellisée LIGUE 2024, Dijon, France.

Frontiers in immunology
|February 16, 2026
PubMed
概括

介质素-1β (IL-1β) 通过增强免疫反应,可能有助于治疗非小细胞肺癌 (NSCLC). 通过化疗免疫疗法激活IL-1β显示出克服NSCLC治疗耐药性的前景.

关键词:
一个IL-1ββ.在NSCLCLC中,我们可以看到.化疗 化疗是一种化学疗法.临床试验是指临床试验中的临床试验.免疫疗法 免疫疗法

更多相关视频

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.1K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...